GW Henssler & Associates Ltd. Acquires 6,547 Shares of Gilead Sciences, Inc. (GILD)

GW Henssler & Associates Ltd. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 167,056 shares of the biopharmaceutical company’s stock after purchasing an additional 6,547 shares during the quarter. Gilead Sciences accounts for approximately 1.4% of GW Henssler & Associates Ltd.’s investment portfolio, making the stock its 24th biggest holding. GW Henssler & Associates Ltd.’s holdings in Gilead Sciences were worth $13,535,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $147,000. Hanson & Doremus Investment Management boosted its stake in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 480 shares in the last quarter. Rowland & Co. Investment Counsel ADV acquired a new position in shares of Gilead Sciences during the 2nd quarter worth about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth about $172,000. 75.94% of the stock is currently owned by institutional investors.

In other news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold a total of 461,666 shares of company stock valued at $34,072,567 in the last three months. 1.30% of the stock is currently owned by corporate insiders.

Several research analysts recently weighed in on the stock. BidaskClub downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a research report on Wednesday, January 3rd. BMO Capital Markets restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, January 3rd. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Finally, Oppenheimer restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, December 21st. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $85.03.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $78.71 on Thursday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27. The company has a market cap of $102,790.00, a P/E ratio of 8.95, a price-to-earnings-growth ratio of -1.58 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the company posted $2.75 EPS. The firm’s revenue was down 13.2% compared to the same quarter last year. equities research analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were given a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.64%. Gilead Sciences’s dividend payout ratio is presently 23.66%.

ILLEGAL ACTIVITY NOTICE: “GW Henssler & Associates Ltd. Acquires 6,547 Shares of Gilead Sciences, Inc. (GILD)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/11/gw-henssler-associates-ltd-acquires-6547-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit